AegirBio AB (AegirBio AB) Debt-to-Equity : -3.52 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is AegirBio AB Debt-to-Equity?

AegirBio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.19 Mil. AegirBio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.36 Mil. AegirBio AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-1.01 Mil. AegirBio AB's debt to equity for the quarter that ended in Mar. 2024 was -3.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AegirBio AB's Debt-to-Equity or its related term are showing as below:

AEGBF' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.52 Med: 0.02 Max: 4.59
Current: -3.52

During the past 4 years, the highest Debt-to-Equity Ratio of AegirBio AB was 4.59. The lowest was -3.52. And the median was 0.02.

AEGBF's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs AEGBF: -3.52

AegirBio AB Debt-to-Equity Historical Data

The historical data trend for AegirBio AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AegirBio AB Debt-to-Equity Chart

AegirBio AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.02

0.18

AegirBio AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.18	0.03	1.28	4.58	-3.52

Competitive Comparison of AegirBio AB's Debt-to-Equity

For the Medical Devices subindustry, AegirBio AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AegirBio AB's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AegirBio AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AegirBio AB's Debt-to-Equity falls into.

AegirBio AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AegirBio AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.648	+	0.041)	/	3.838
	=	0.18

AegirBio AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.194	+	3.364)	/	-1.012
	=	-3.52

AegirBio AB (GREY:AEGBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AegirBio AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AegirBio AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AegirBio AB (AegirBio AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AegirBio AB (GREY:AEGBF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AEGIR:Sweden 52Q:Germany

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.aegirbio.com

AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.

AegirBio AB (AegirBio AB) Headlines

No Headlines